Impressive progress in treating high cholesterol

High harmful cholesterol is considered one of the main causes of narrowing of the coronary arteries that feed the heart and the carotid arteries that feed the brain and all other arteries in the body, which leads to the narrowing of these arteries, and their blockage leads to heart attacks, strokes, or death of the lower extremities (gangrene) and ulcers.

Statins are considered the main treatment for reducing harmful cholesterol, in addition to diet and exercise.
But many patients experience side effects from statins, such as muscle pain, or this medication is not sufficient to sufficiently lower harmful cholesterol.
The major advance in treating high cholesterol is medications given by subcutaneous injection.
These medications have been shown to be highly effective, and do not have many side effects.
One of the most prominent of these medications is a drug called **evolocumab**.
The second medicine is called **alirocumab**.
PCSK9 is a protein called PCSK9, and these drugs work fine
This makes the liver more effective in removing harmful cholesterol from the blood.
These injections are given once or twice a month, and have been shown to be very effective and well tolerated by patients. From my personal experience, I have used these medications for patients over the past nearly ten years with excellent results.
PCSK9 There is another new type called **Inclisran**, which works by reducing the production of…
This injection is given under the skin only twice a year. This injection has treated a large number of patients, and its safety has been shown to be half that. LDL levels are reduced
The main problem with all of these injections is their high price, which reduces their spread. They may become more widespread if their price drops to be more widely available.
Often these injections can be given in addition to statins to some patients whose cholesterol is not sufficiently reduced.
Adding these needles reduces cholesterol to the required number in the vast majority of patients.
Based on recent recommendations from the **American Heart Association** and **European Heart Association**, the level of harmful cholesterol should be less than **55 mg/dL** in patients who have narrowings in the arteries of the heart, brain, or any other arteries in the body.
Many of these patients need to combine statins with other cholesterol-lowering medications because it is difficult to achieve these levels with statins alone.